An Introduction to Costeffectiveness
|
|
- Adelia Susan Brown
- 5 years ago
- Views:
Transcription
1 Health Economics: An Introduction to Costeffectiveness Analysis Subhash Pokhrel, PhD Reader in Health Economics Director, Division of Health Sciences
2 Why do we need economic evaluation?
3 Patient demand Most goods and services are rationed by price, and people decide how to use their own money But market failures mean that health services are better provided collectively So health interventions are provided at zero or subsidised cost at point of consumption
4 Balancing supply and demand This can cause an imbalance between patients demands and the system s ability to provide So we need other mechanisms to ration health care resources
5 Informal rationing mechanisms Klein, Day & Redmayne 1996 Denial Selection Deflection Deterrence Delay Dilution Termination Exclusion criteria (e.g. age limit for dialysis) Inclusion criteria (e.g. smoking behaviour and access to surgery) Cost shifting (e.g. health/social) Access barriers (e.g. co-payment) Waiting lists Reduced service quantity/quality for users Premature cessation of service
6 Formal rationing mechanisms Price Access by ability to pay Clinical need Prioritise sickest patients Clinical benefit Prioritise patients with highest expected health gain Cost effectiveness Balance health gain against cost
7 Opportunity costs If a health service spends more on one thing, it has to do less of something else Opportunity cost = value of the best alternative use of resources
8 The opportunity cost of one course of IVF? One-third of a cochlear implant 1 heart bypass operation 11 cataract removals 150 childhood vaccinations Half a teaching assistant for a year 2000 school dinners One-thousandth of a Challenger tank Source: Morris et al
9 The decision problem Economic evaluations are designed to inform decisions. >Distinction from traditional research which is designed to test hypotheses. Need to specify the decision problem that the economic evaluation will address >Identify decision maker, the relevant perspective; the relevant comparator interventions and the metrics by which to compare them
10 What is economic evaluation?
11 Economic Evaluation... the comparative analysis of alternative courses of action in terms of both their costs and consequences. Drummond, Stoddart & Torrance, 1987 Costs value of extra resources used (loss to other patients) Current programme New programme Consequences value of health gain for this patient group
12 Main types of Economic Evaluation Type of analysis Valuing resources Valuing health outcomes Application Cost minimisation - Comparison of interventions with similar clinical effects Cost effectiveness Single indicator of morbidity or mortality Comparison of interventions which differ on one, and only one, measure of effect Cost utility Index of morbidity and mortality (QALY) Comparison of any health care interventions: may trade off health effects Cost benefit Comparison of any health or non-health interventions
13 How to conduct a good economic evaluation Define the decision problem Framing the question Specify who the decision maker is and what perspective they are concerned with Identify which patients should be included > Define population at point in pathway > Consider subgroups & risk stratification Choose the right interventions and comparators > Include all relevant options > Current practice, usual care > Do nothing, best supportive care, placebo? Include all relevant costs and health effects > Identify all significant costs and savings > Select appropriate measure(s) of outcome
14 How to conduct a good economic evaluation? Drummond s criteria The Drummond Checklist Well-defined study question? Comprehensive description of alternatives? Effectiveness established? Important costs/consequences identified? Costs/consequences measured accurately? Costs/consequences valued credibly? Discounting? Incremental analysis? Treatment of uncertainty? Discussion of other issues?
15 Economic Evaluation in Health Care Cost-effectiveness Identification of resources/costs & outcomes Measurement Valuation Comparison
16 Sources of Evidence Literature Existing trials New trials Systematic reviews Meta-analyses Indirect comparisons Data-bases and registries Observational studies Expert opinion Patient views etc
17 Economic evaluation alongside trials Clinical trials can provide much of the evidence required for an economic evaluation Outcomes Clinical outcomes e.g. functioning scores, pain Final outcomes e.g. mortality, life years QOL e.g. disease specific, generic, utility Resource use Hospitalisations Medicines Adverse events
18 Selecting a Health Outcome Measure Depends on the research question and the type of economic evaluation What measures will capture important benefits? Mortality Clinical measures Disease specific QoL Generic QoL measure Utility measure Considerations based on disease area and interventions
19 Assumes: What is a QALY? 1 QALY = one year of life in full health >People can trade-off length of life vs quality of life e.g. 1 QALY = 2 years with 50% QoL for one person >Each year of healthy life is of equal value for all e.g. 1 QALY = 6 months of healthy life for two people Public health 25,000 people, 0.01 QALYs per year for 20 years = 5,000 QALYS Heart surgery 5,000 people, 0.1 QALYs per year for 10 years = 5,000 QALYS
20 Health-related quality of life The Quality Adjusted Life Year 1 Initial QALY loss due to side effects QALYs gained Current treatment New treatment 0 Length of life (years)
21 Putting the Q in QALY Main types of utility measurement Direct elicitation methods (Time trade-off, Standard gamble, VA) Pre-scored preference assessment instruments (most frequently used) Special form of generic outcome measure Provides a single index utility value (0= death, 1 = full health) Can be used to combines survival with health related QoL to give quality adjusted life years (QALY)
22 EQ-5D: Dimensions and Levels Five dimensions: Mobility, Self care, Usual activities, Pain/discomfort, Anxiety/depression Three / Five levels each: No problem, Some/moderate problem, Extreme problem/unable No, slight, moderate, severe, extreme 243 / 3125 possible health states
23 EQ-5D By placing a tick in one box in each group below, please indicate which statements best describe your own health state today. Mobility I have no problems in walking about I have some problems in walking about I am confined to bed Self-Care I have no problems with self-care I have some problems washing or dressing myself I am unable to wash or dress myself Usual Activities (e.g. work, study, housework, family or leisure activities) I have no problems with performing my usual activities I have some problems with performing my usual activities I am unable to perform my usual activities Pain/Discomfort I have no pain or discomfort I have moderate pain or discomfort I have extreme pain or discomfort Anxiety/Depression I am not anxious or depressed I am moderately anxious or depressed I am extremely anxious or depressed
24 Resources/Costs Which costs are relevant? Cost-effective for whom? Provider s perspective: materials, heating, lightning, supervision, training, bed stays Staff time: Cost of therapy time per face-to face contact, non-face to face time Service user / family perspective: productivity losses, time, travel costs Wider society perspective: effect on other providers and services, benefits
25 Resource/Cost Estimates Identify event pathways (e.g. control and intervention arms) Measure resources required (staff, equipment, consumables etc) Ascertain unit costs Apply unit costs to the resources used in each pathway
26 Making choices The use of economic evaluation
27 Trading off benefits, harms and costs Dominated more expensive & worse Current treatment Cost ( ) Better but more expensive New treatment Effect (QALYs) Dominant cheaper & better
28 ... but is it cost-effective? Cost ( ) No small health gain/ Yes big health gain/ Effect (QALYs)
29 The Cost per QALY Incremental Cost Effectiveness Ratio (ICER) Cost ( ) ICER = Extra cost QALYs gained Extra cost QALYs gained Effect (QALYs)
30 How much can/should we pay for a QALY? Cost-effectiveness threshold (λ) Cost ( ) Effect (QALYs) NICE threshold: 20,000 to 30,000 per QALY
31 The decision rule Intervention (1) cost-effective vs. comparator (0) if: ICER = (C 1 C 0 ) (E 1 E 0 ) < λ Or equivalently use Incremental Net Benefit (INB) INB = λ (E 1 E 0 ) - (C 1 C 0 ) >
32 NICE approach to EE: Methods Manual (NICE, 2013) 1/2 Element of health technology assessment Defining the decision problem Comparator(s) Reference case Section providing details The scope developed by NICE to As listed in the scope developed by NICE Perspective on outcomes All direct health effects, whether for patients or, when relevant, carers to 2.2.6, 5.1.6, , Perspective on costs NHS and PSS and Type of economic Cost utility analysis with fully to evaluation incremental analysis Time horizon Synthesis of evidence on health effects Long enough to reflect all important to differences in costs or outcomes between the technologies being compared Based on systematic review 5.2 some slides in this deck courtesy of: HERG Short Course 32
33 NICE approach to EE: Methods Manual (NICE, 2013) 1/2 Element of health technology assessment Reference case Section providing details Measuring and valuing health effects Source of data for measurement of health-related quality of life Health effects should be expressed in QALYs.The EQ-5D is the preferred measure of health-related quality of life in adults. Reported directly by patients and/or carers Source of preference data for valuation of changes in healthrelated quality of life Equity considerations Representative sample of the UK population An additional QALY has the same weight regardless of the other characteristics of the individuals receiving the health benefit Evidence on resource use and costs Costs should relate to NHS and PSS resources and should be valued using the prices relevant to the NHS and PSS Discounting The same annual rate for both costs and health effects (currently 3.5%) some slides in this deck courtesy of: HERG Short Course 33
34 Introduction to economic evaluation Summary Some form of rationing explicit or implicit is inevitable NICE and some other HTA bodies, are making cost-effectiveness a much more explicit criterion Methods of economic evaluation differ principally in the way effects are measured Cost per QALY is most useful for making decisions within fixed budget at health service level But only CBA can be used to compare health with non-health policies If economic evaluation is to be used to inform decision-making, it needs to be high quality and appropriate
35 Thinking to do a cost-effectiveness analysis?
36 Ask yourself a couple of questions: 1. Do you know what your decision problem is? Population, Intervention, Comparator, Outcomes 2. Do you know you have adequate support? Engage with health economists
37 Health Economists??
38 Health Economists Wikipedia definition: In broad terms, health economists study the functioning of healthcare systems and health-affecting behaviours such as smoking But, Core skills Economics; Number crunching; Modelling; econometrics (other name for stats!); study designs; measurement of costs and health outcomes Learnt skills Applied epidemiology; disease and treatment (causes; prognosis; care pathways, etc. etc. )
39 Engaging with health economists?? Speak to colleagues for a recommendation! Do you need a generalist? Do you need a specialist? Engage early! Avoid this - We have a grant application going in tomorrow. I wonder whether you would like to collaborate as a health economist? Please provide a paragraph on health economic analysis first thing tomorrow Seek advice on your design, yes, right from the beginning! Health economists often have ideas about several important aspects of your study such as RCTs; measuring outcomes; data management, analysis, etc. etc. Alone we can do so little; together we can do so much (Helen Keller)
40 Some areas where collaboration with health economists may be useful: Cost analysis Within trial analysis Measuring / Modelling long term outcomes Cost-effectiveness analysis Analysis of existing fiscal data alongside service outcomes data Developing pilots Testing interventions Reviewing your work
41 Next courses 9-11 May Nov
42 Individually tailored internships/placements Visiting researcher 3-6 months placement at Brunel Do short course Allocated supervisor Exit with a tangible outcome Fully developed research protocol Fully developed analysis Manuscript ready for submission to journals
43 Collaborative research at HERG Partner in research proposal that is led by clinicians Inputs from design to execution with regard to health economics Support on other areas related to analysis and critical reviews Senior Health Economist supported by a RA/RF NIHR, RCUK, and other funders
Food for thought. Department of Health Services Research 1
Food for thought Suppose you have been asked to undertake an economic evaluation of the costs and effects on the Fall prevention program Identify the range of different costs that you might wish to include
More informationLIHS Mini Master Class
Alexandru Nicusor Matei 2013 CC BY-NC-ND 2.0 Measurement and valuation of health using QALYS John O Dwyer Academic Unit of Health Economics John O Dwyer University of Leeds 2015. This work is made available
More informationPharmacoeconomics: from Policy to Science. Olivia Wu, PhD Health Economics and Health Technology Assessment
Pharmacoeconomics: from Policy to Science Olivia Wu, PhD Health Economics and Health Technology Assessment Potential conflicts of interest - none 2 Pharmacoeconomics: from policy to science - Why the need
More informationBasic Economic Analysis. David Epstein, Centre for Health Economics, York
Basic Economic Analysis David Epstein, Centre for Health Economics, York Contents Introduction Resource use and costs Health Benefits Economic analysis Conclusions Introduction What is economics? Choices
More informationUsing Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC
Using Health Economics to Inform the Development of Medical Devices Matthew Allsop MATCH / BITECIC Overview Background to MATCH Overview of health economics in product development Concepts relating to
More informationCost-Utility Analysis (CUA) Explained
Pharmaceutical Management Agency Cost-Utility Analysis (CUA) Explained Cost-Utility Analysis (CUA) at PHARMAC Questions and Answers go to page 9 >> This document explains the process that PHARMAC generally
More informationLondon Pathway Evaluation
Digestive Disorders Clinical Academic Unit Endoscopy Unit The Royal London Hospital Whitechapel London E1 1BB Tel: 020 7377 7218 Main switchboard: 020 7377 7000 The Trial Homeless people, outcomes questionnaire
More informationNICE Guidelines for HTA Issues of Controversy
NICE Guidelines for HTA Issues of Controversy Mark Sculpher, PhD Professor of Health Economics University of York, UK LMI, Medicines Agency in Norway and the Norwegian Knowledge Centre for the Health Services:
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationNICE decisions on health care provisions in England
NICE decisions on health care provisions in England Matt Stevenson, Professor of Health Technology Assessment (HTA), ScHARR, University of Sheffield, UK A quick introduction I am Technical Director of
More informationThe Cost-Effectiveness of Individual Cognitive Behaviour Therapy for Overweight / Obese Adolescents
Dr Marion HAAS R Norman 1, J Walkley 2, L Brennan 2, M Haas 1. 1 Centre for Health Economics Research and Evaluation, University of Technology, Sydney. 2 School of Medical Sciences, RMIT University, Melbourne.
More informationSession 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples
Session 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples - Madeleine King & Richard De Abreu Lourenco- Overview Learning Objectives To discuss
More informationHas Consumer Directed Care improved the quality of life of older Australians? Professor Julie Ratcliffe School of Medicine Flinders University
Has Consumer Directed Care improved the quality of life of older Australians? Professor Julie Ratcliffe School of Medicine Flinders University Acknowledgments: ARC Linkage Project A Health Economics Model
More informationQu est-ce que la santé? Regard critique sur les QALYs et analyse d autres paramètres pour mesurer les gains en santé
Chaire Francqui: leçon 5 Qu est-ce que la santé? Regard critique sur les QALYs et analyse d autres paramètres pour mesurer les gains en santé Lieven Annemans ULB, 17 mai 2017 The goal of health care systems
More informationIntroduction. Onco-Pharmacoeconomy Training Course. Turkey ISPOR Training Course
Onco-Pharmacoeconomy Training Course Turkey ISPOR Training Course Introduction Dr Alan Haycox Reader in Health Economics Health Economics Unit University of Liverpool Management School Course objectives
More informationYour Health Survey. Forename: Surname: Renal Unit: Type of treatment: If HD, are you: Date of birth: Home Post Code: Date completed: NHS number:
Your Health Survey Why this questionnaire You may already have heard about renal units introducing health questionnaires. The purpose of these questionnaires is to find out how your kidney disease affects
More informationA. Introduction to Health Economics. Dr Alan Haycox Reader in Health Economics Health Economics Unit University of Liverpool Management School
A. Introduction to Health Economics Dr Alan Haycox Reader in Health Economics Health Economics Unit University of Liverpool Management School Introduction to Health Economics Programme The programme will
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationUsing CEA to inform state policy 30 November 2017
E: jshoch@ucdavis.edu T: @j_hoch https://twitter.com/j_hoch USING COST- EFFECTIVENESS ANALYSIS TO INFORM STATE POLICY Health Policy and Management Jeffrey S. Hoch, PhD Associate Director, Center for Healthcare
More informationAn exploration of the cost-effectiveness of interventions to reduce. differences in the uptake of childhood immunisations in the UK using
An exploration of the cost-effectiveness of interventions to reduce differences in the uptake of childhood immunisations in the UK using threshold analysis National Collaborating Centre for Women s and
More informationThe cost of cancer treatment
The cost of cancer treatment Lieven Annemans Ghent University Lieven.annemans@ugent.be January 2016 What s the problem? those prices are too high the budgets will explode these drugs offer survival benefit
More informationKAISER PERMANENTE SPINE
KAISER PERMANENTE SPINE The following forms are specially designed to give your doctor valuable information about the health of your spine. The same way an EKG gives us information about your heart. It
More informationTechnology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta459
Collagenase clostridium histolyticum for treating Dupuytren's contracture Technology appraisal guidance Published: 26 July 2017 nice.org.uk/guidance/ta459 NICE 2017. All rights reserved. Subject to Notice
More informationPlease return the questionnaire in the enclosed pre-paid envelope
Instructions Please complete the questionnaire, making sure you reply to all the questions. This should take you about 20 minutes. If you have difficulties completing the questionnaire, please ask someone
More informationTechnology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476 NICE 2018. All
More informationKAISER PERMANENTE SPINE
KAISER PERMANENTE SPINE The following forms are specially designed to give your doctor valuable information about the health of your spine. The same way an EKG gives us information about your heart. It
More informationTechnology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta448
Etelcalcetide for treating secondary hyperparathyroidism Technology appraisal guidance Published: 28 June 2017 nice.org.uk/guidance/ta448 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationImproving trial methodology: Examples from epilepsy. Tony Marson University of Liverpool
Improving trial methodology: Examples from epilepsy Tony Marson University of Liverpool This talk Examples of trial methodology research Focus on epilepsy but Examples are relevant to any field Epilepsy
More informationIn keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:
Advice Statement 009-18 July 2018 Advice Statement What is the clinical and cost effectiveness of Freestyle Libre flash glucose monitoring for patients with diabetes mellitus treated with intensive insulin
More informationHealth Services Research and Health Economics. Paul McCrone Institute of Psychiatry, King s College London
Health Services Research and Health Economics Paul McCrone Institute of Psychiatry, King s College London Key Questions What is the rationale for considering health economics? What are the key components
More informationRADPAR WP 7: Cost-effectiveness
RADPAR WP 7: Cost-effectiveness May 2012: Final Report: Analysis of cost effectiveness and health benefits of radon control strategies Version 3 This publication arises from the project Radon Prevention
More informationAppendix 18d: Computerised cognitive behavioural therapy for panic disorder GRADE evidence profiles
: Computerised cognitive behavioural therapy for panic disorder GRADE evidence profiles versus waitlist control for panic disorder... 2 versus information control for panic disorder... 3 versus any control
More informationTechnology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 NICE 2018. All rights reserved. Subject to
More informationEconomic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women
Y O R K Health Economics C O N S O R T I U M NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Economic Analysis of Interventions for Smoking Cessation Aimed at Pregnant Women Supplementary Report
More informationTechnology appraisal guidance Published: 15 December 2010 nice.org.uk/guidance/ta211
Prucalopride for the treatment of chronic constipation in women Technology appraisal guidance Published: 15 December 2010 nice.org.uk/guidance/ta211 NICE 2018. All rights reserved. Subject to Notice of
More informationSession 6. Evaluating the Cost of Pharmaceuticals
Drug and Therapeutics Committee Training Course Session 6. Evaluating the Cost of Pharmaceuticals Trainer s Guide Drug and Therapeutics Committee Training Course Trainer s Guide This document was made
More informationLondon Pathway Evaluation
Digestive Disorders Clinical Academic Unit Endoscopy Unit The Royal London Hospital Whitechapel London E1 1BB Tel: 020 7377 7218 Main switchboard: 020 7377 7000 The Trial Homeless people, outcomes questionnaire
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442
Ixekizumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 NICE 2017. All rights reserved. Subject to Notice of rights
More informationHealth economics for device developers: a framework for assessing commercial viability
Health economics for device developers: a framework for assessing commercial viability Amanda Chapman & Samantha Burn University of Birmingham, UK. WHO Global forum on medical devices 23 rd November 2013
More informationUsing pilot economic models to support grant applications for clinical trials:
Using pilot economic models to support grant applications for clinical trials: a case study of STRATA project Huajie Jin (Lily) Senior health economist Centre for the Economics of Mental and Physical Health
More informationTHERAPY WORKSHEET: page 1 of 2 adapted from Sackett 1996
THERAPY WORKSHEET: page 1 of 2 adapted from Sackett 1996 Citation: Are the results of this single preventive or therapeutic trial valid? Was the assignment of patients to treatments randomised? -and was
More information1. Comparative effectiveness of liraglutide
Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding
More informationTechnology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation- positive non-small-cell lung cancer Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416 NICE
More informationCost-effectiveness Analysis for HHS
Cost-effectiveness Analysis for HHS Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID ASSIST Project, University Research Co., LLC Ukraine: 1 Mali: 1 Nigeria: 1 2 Uganda: 6 Burundi:
More informationCost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) The NCPE has issued a recommendation regarding the cost-effectiveness of tolvaptan (Jinarc
More informationA Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
Presenter: Chris Cameron CANNeCTIN November 8, 2013 A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making Acknowledgements Vanier
More informationSetting The setting was secondary care. The study was carried out in the UK, with emphasis on Scottish data.
Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan
More informationHealth Economics 101: PPI prescriptions in the Emergency Room
: PPI prescriptions in the Emergency Room Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Presented by: Chris Cameron October 26, 2007 What is Health Economics? Health economics
More informationNICE DSU TECHNICAL SUPPORT DOCUMENT 8: AN INTRODUCTION TO THE MEASUREMENT AND VALUATION OF HEALTH FOR NICE SUBMISSIONS
NICE DSU TECHNICAL SUPPORT DOCUMENT 8: AN INTRODUCTION TO THE MEASUREMENT AND VALUATION OF HEALTH FOR NICE SUBMISSIONS REPORT BY THE DECISION SUPPORT UNIT August 2011 John Brazier 1 and Louise Longworth
More informationBackground Comparative effectiveness of ibrutinib
Cost effectiveness of ibrutinib (Imbruvica ) in the treatment of patients with chronic lymphocytic leukaemia who have received 1 prior therapy, or as a first-line treatment in the presence of del(17p)
More informationSmoking cessation interventions and services
National Institute for Health and Care Excellence Guideline version (Final) Smoking cessation interventions and services [E] Evidence reviews for advice NICE guideline NG92 Evidence reviews FINAL These
More informationFolland et al Chapter 4
Folland et al Chapter 4 Chris Auld Economics 317 January 11, 2011 Chapter 2. We won t discuss, but you should already know: PPF. Supply and demand. Theory of the consumer (indifference curves etc) Theory
More informationUstekinumab for the treatment of moderate to severe psoriasis
DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441
Daclizumab for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441 NICE 2017. All rights reserved. Subject to Notice of rights
More informationCritical Appraisal Skills. Professor Dyfrig Hughes Health Economist AWMSG
Critical Appraisal Skills Professor Dyfrig Hughes Health Economist AWMSG Critical appraisal of economic evaluations Quality of the underlying evidence Quality of the analysis Quality of reporting 1. Quality
More informationTechnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471
Eluxadoline for treating irritable bowel syndrome with diarrhoea Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 NICE 2017. All rights reserved. Subject to Notice of
More informationIntroduction to Cost-Effectiveness Analysis
Introduction to Cost-Effectiveness Analysis Janie M. Lee, MD, MSc RSNA Clinical Trials Methodology Workshop January 13, 2016 Why is Clinical Research Important to Radiology? Radiology currently occupies
More informationImpact of health behaviours and health interventions on demand for and cost of NHS services in the North of Scotland (including Tayside)
Impact of health behaviours and health interventions on demand for and cost of NHS services in the North of Scotland (including Tayside) Note: This paper is based on a report originally produced by Dr
More informationSetting The setting was institutional and tertiary care in London, Essex and Hertfordshire in the UK.
Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, Orrell M Record Status This is a critical abstract of
More informationThe HTA challenge of medical device assessment: The perspective of assessor
The HTA challenge of medical device assessment: The perspective of assessor Rod Taylor Associate Professor in Health Services Research & Scientific Director of Peninsula Clinical Trials Unit Peninsula
More informationMPhil/PhD Application Form
Department of Economics MPhil/PhD Application Form Please enter your full correspondence details here: Applicant (Student) Details Title (Mr, Miss, Mrs) Forename Surname Telephone No. Fax No. Email Address
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationCost-effectiveness ratios are commonly used to
... HEALTH ECONOMICS... Application of Cost-Effectiveness Analysis to Multiple Products: A Practical Guide Mohan V. Bala, PhD; and Gary A. Zarkin, PhD The appropriate interpretation of cost-effectiveness
More informationTechnology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499
Glecaprevir pibrentasvir for treating chronic hepatitis C Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta499 NICE 2018. All rights reserved. Subject to Notice of rights
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationAppraisals. What is a NICE Technology Appraisal? Logo Here
Add A view your from Presentation NICE: Technology Title Here.. Appraisals Add Helen your Knight, name 9 and May organisation 2013 Logo Here What is a NICE Technology Appraisal? A review of clinical and
More informationMaking Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions
Making Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics University of York, UK Outline Policy context
More informationTechnology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325
Nalmefene for reducing alcohol consumption in people with alcohol dependence Technology appraisal guidance Published: 26 November 2014 nice.org.uk/guidance/ta325 NICE 2018. All rights reserved. Subject
More informationCombination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary
Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized
More informationTechnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta456
Ustekinumab for moderately to severelyerely active Crohn s disease after previous treatment Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta456 NICE 2017. All rights reserved.
More informationTechnology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516
Cabozantinib for treating medullary thyroid cancer Technology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationEconomic Analyses in Clinical Trials
Economic Analyses in Clinical Trials Natasha Leighl (and Nicole Mittmann) Committee on Economic Analysis, NCIC CTG Natasha.Leighl@uhn.on.ca; Nicole.Mittmann@sunnybrook.ca Financial Disclosures Research
More informationPeginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106
Issue date: September 2010 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Part review of NICE technology appraisal guidance 75 and 106 National Institute for Health and Clinical
More informationTechnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 NICE 2017. All rights
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationSocial Values and Health Priority Setting Case Study
Social Values and Health Priority Setting Case Study Title of Case Study Author Author Contact Novo Seven in haemophilia: clinical decision making and funding policies in Germany Author: Dr Alena Buyx,
More informationNICE guidelines development Low back pain and sciatica: Management of non-specific low back pain and sciatica
NICE guidelines development Low back pain and sciatica: Management of non-specific low back pain and sciatica Steven Vogel Vice Principal (Research), The British School of Osteopathy Editor-in-Chief, The
More informationVaricose Veins Surgery Questionnaire
REV_VaricoseVeins_12pp_Q_PostOp 29/10/09 Page 1 Varicose Veins Surgery Questionnaire After your operation About three months ago you had a Varicose Veins Operation. You may remember that you agreed that
More informationTechnology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507
Sofosbuvir velpatasvir voxilaprevir for treating chronic hepatitis C Technology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507 NICE 2018. All rights reserved. Subject to Notice
More informationTechnology appraisal guidance Published: 25 January 2017 nice.org.uk/guidance/ta431
Mepolizumab for treating severeere refractory eosinophilic asthma Technology appraisal guidance Published: 25 January 2017 nice.org.uk/guidance/ta431 NICE 2017. All rights reserved. Subject to Notice of
More informationThe economics of mental health
The economics of mental health Professor Martin Knapp - Professor of Social Policy, London School of Economics and Political Science Michael Parsonage - Chief Economist, Centre for Mental Health Mental
More informationHealth technology The use of tension-free vaginal tape (TVT) for the treatment of female stress urinary incontinence (SUI).
Cost effectiveness of tension-free vaginal tape for the surgical management of female stress incontinence Kilonzo M, Vale L, Stearns S C, Grant A, Cody J, Glazener C M, Wallace S, McCormack K Record Status
More informationType of intervention Secondary prevention and treatment; Other (medication coverage policy design).
Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes Rosen A B, Hamel M B, Weinstein M C, Cutler D M, Fendrick A, Vijan S Record Status
More informationSetting The setting was secondary care. The economic study appears to have been conducted in the UK.
One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial Weintraub W S, Mahoney E M, Zhang Z, Chu H, Hutton J, Buxton M, Booth J, Nugara
More informationWhat does it mean for innovative technologies/medicines? Health economic evaluations and their role in health care decision making.
Health economic evaluations and their role in health care decision making. Lieven Annemans Ghent University Lieven.annemans@ugent.be December 204 2 Health expenditure is recognised as growthfriendly expenditure.
More informationTechnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411 NICE 2017. All rights reserved.
More informationCost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy
Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy The NCPE has issued a recommendation regarding the cost-effectiveness
More informationQALYs and the QALY problem in PC. 1. Idea of the QALY 2. QALY problem in Palliative Care
QALYs and the QALY problem in PC 1. Idea of the QALY 2. QALY problem in Palliative Care QALYs and the QALY problem in PC 1. Idea of the QALY 2. QALY problem in Palliative Care Idea of the QALY In a single
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following
More informationBackground Comparative effectiveness of nivolumab
NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued
More informationCost-effectiveness of cladribine (Mavenclad ) for the
Cost-effectiveness of cladribine (Mavenclad ) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features The NCPE has issued a recommendation
More informationEconomic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T
Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationSetting The setting was primary care. The economic study was carried out in the UK.
A cost-utility analysis of multivitamin and multimineral supplements in men and women aged 65 years and over Kilonzo M M, Vale L D, Cook J A, Milne A C, Stephen A I, Avenell A Record Status This is a critical
More informationTechnology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380
Panobinostat for treating multiple myeloma after at least 2 previous treatments Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380 NICE 2017. All rights reserved. Subject
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440 NICE 2017. All rights reserved. Subject
More informationSummary Background 1. Comparative effectiveness of ramucirumab
Cost-effectiveness of ramucirumab (Cyramza ) for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression following previous treatment
More informationCost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages.
Cost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages. The NCPE has issued a recommendation regarding the cost-effectiveness of elosulfase alfa
More informationMesothelioma Outcomes, Research and Experience survey (MORE Survey).
Mesothelioma Outcomes, Research and Experience survey (MORE Survey). Mesothelioma UK would like to invite mesothelioma patients to have the opportunity to describe what their experience of investigations,
More information